文献速递神经核医学核素与放射性配体治疗肿瘤 PET/CT

胶质母细胞瘤诊疗一体化:FAPI-46作为精准医学工具的转化研究

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool.
PubMed 文献 · J Nucl Med · 2026-09-02

本研究在胶质母细胞瘤模型中评估FAP靶向探针FAPI-46的诊疗潜力。结果示[68Ga]Ga-FAPI-46在皮下移植瘤中高摄取,[225Ac]Ac-FAPI-46联合替莫唑胺可延长生存,但原位移植瘤和患者中摄取低,提示血脑屏障穿透有限。

要点

  • 皮下模型中[68Ga]Ga-FAPI-46肿瘤摄取高、背景信号低。
  • 免疫缺陷模型单剂[225Ac]Ac-FAPI-46联合替莫唑胺即可延长中位生存。
  • 原位模型和患者中[68Ga]Ga-FAPI-46摄取低,血脑屏障穿透有限。

核心结论

  • FAPI-46在外周模型中作为胶质母细胞瘤诊疗一体化剂有显著潜力。
  • FAPI-46无法穿越血脑屏障,原位模型和患者中肿瘤浓度可能过低而难以达到治疗效果。

研究设计与样本

  • 使用人U-87 MG和小鼠SB28胶质母细胞瘤细胞系建立免疫缺陷和免疫健全模型。
  • FAPI-46分别用68Ga标记用于显像、用225Ac或177Lu标记用于治疗。
  • 临床前评估肿瘤摄取、疗效、免疫调节效应和生存,并评估患者中[68Ga]Ga-FAPI-46肿瘤摄取。

主要发现

  • 皮下移植瘤中[68Ga]Ga-FAPI-46肿瘤摄取高、背景信号低。
  • 免疫缺陷模型中单剂[225Ac]Ac-FAPI-46联合替莫唑胺足以提高中位生存。
  • 免疫健全模型中需连续3天每日给药才能获得显著生存获益。
  • [177Lu]Lu-FAPI-46单用或联合替莫唑胺的疗效低于[225Ac]Ac-FAPI-46。
  • 流式细胞术评估的免疫调节效应不足以克服免疫「冷」的胶质母细胞瘤微环境。

临床怎么用

  • FAPI-46在外周胶质母细胞瘤模型中具诊疗一体化潜力,但血脑屏障穿透限制其临床转化。

局限性

  • 原位移植瘤和患者中[68Ga]Ga-FAPI-46摄取低,提示血脑屏障穿透有限。
  • 免疫调节效应不足以克服免疫「冷」的胶质母细胞瘤微环境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma represents the most lethal form of brain cancer, characterized by a 5-y survival rate of approximately 4%. Fibroblast activation protein (FAP), expressed within both the tumor microenvironment and glioblastoma cells, has been identified as a promising therapeutic target. This study explores the potential of FAP-targeted molecular probes as theranostic agents for glioblastoma. Methods: Human U-87 MG and murine SB28 glioblastoma-derived cell lines were used to establish immunodeficient and immunocompetent models, respectively. FAP inhibitor (FAPI)-46 was radiolabeled with 68Ga for imaging and 225Ac or 177Lu for therapy. Tumor uptake, therapeutic efficacy, immunomodulatory effects, and survival were evaluated for FAPI-46 alone or in combination with temozolomide in preclinical studies. [68Ga]Ga-FAPI-46 tumor uptake was also evaluated in patients. Results: In subcutaneous xenografts, [68Ga]Ga-FAPI-46 exhibited high tumor uptake with minimal background signal. In the immunocompromised model, a single dose of [225Ac]Ac-FAPI-46 combined with temozolomide was sufficient to increase median survival, whereas in the immunocompetent model, 3 consecutive daily doses were required to achieve a significant survival benefit. [177Lu]Lu-FAPI-46 demonstrated lower therapeutic efficacy, as a monotherapy or in combination with temozolomide, than did [225Ac]Ac-FAPI-46. Immunomodulatory effects, assessed via flow cytometry, were insufficient to overcome the immunologically "cold" glioblastoma tumor microenvironment. In orthotopic xenografts and patients, [68Ga]Ga-FAPI-46 showed low uptake, indicating limited blood-brain barrier penetration and resulting in tumor concentrations likely too low for therapeutic efficacy. Conclusion: FAPI-46 demonstrates significant potential as a theranostic agent for glioblastoma in peripheral models. However, its inability to cross the blood-brain barrier in orthotopic models highlights the need for future studies to improve its clinical applicability.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jeanjean P, Swaidan A, Tse C, et al. Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. J Nucl Med. 2026. PMID: 42242868. doi:10.2967/jnumed.125.271759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。